LakePharma Announces Its 2019 Symposium AgendaAdded On: 2019-07-30
LakePharma Announces Expansion into the Dallas/Fort Worth MetroplexAdded On: 2019-07-23
November 5th, 2019
November 5, 2019 | 10:30AM PT, 1:30PM ET | Register Here >>
- Hua Tu, Ph.D., President and CEO, LakePharma
- Steven Bye, Marketing Manager, Roche CustomBiotech
Variation in glycosylation can impact the safety and efficacy profiles of a therapeutic protein. Moreover, proper glycosylation can save companies valuable time and money, as less product ends up in bioproduction waste streams. Historically, glycosylation has been managed by cell line development and culture optimization—a process that can be time-consuming and negatively influence protein yield. Roche CustomBiotech has developed an in vitro glycoengineering (IVGE) process and reagents that can enrich certain glycoforms in downstream processing using discrete enzymatic reactions with clear kinetics and predictable outcomes. The IVGE approach decouples glycosylation from the entangled processes of fermentation. Thus, separating glycosylation management from fermentation allows greater control of each and the ability to optimize both glycosylation and yield.
In this GEN webinar, our expert panelist from LakePharma will present data from several successful case studies that have applied the IVGE process to gram scale antibody production.